Merck Just Found a New Way to Outflank Pfizer's Vaccine Empire
The FDA just gave Merck's CAPVAXIVE vaccine a pediatric expansion for high-risk kids aged 2-17, cracking open a door that Pfizer's Prevnar franchise had locked shut. In the multibillion-dollar pneumococcal vaccine war, Merck's adult-optimized shot now has a foothold across the age spectrum.
A Vaccine Designed for Adults Just Got a Kid-Sized Upgrade
Exactly one year ago, Merck crashed Pfizer's pneumococcal vaccine party with CAPVAXIVE, a shot built from the ground up to protect adults against the bacterial strains actually making them sick. On Thursday, the FDA handed Merck something Pfizer doesn't have: a pediatric foothold for its next-generation pneumococcal vaccine.
The agency approved CAPVAXIVE for children and adolescents aged 2 to 17 who have chronic medical conditions that put them at higher risk for pneumococcal disease. Think kids with diabetes, chronic heart disease, kidney problems, or lung conditions. These aren't healthy kids getting a routine shot; they're the ones most likely to end up in the hospital when bacteria slip past their defenses.
And that distinction matters more than you'd think.
The Kids Who Fall Through the Cracks
Pneumococcal disease is caused by Streptococcus pneumoniae, a bacterium that can invade the bloodstream, lungs, and brain. Modern childhood vaccines have crushed infection rates in healthy kids. But children with chronic illnesses? They're a different story entirely.
Kids with conditions like sickle cell disease or immunodeficiency can face infection rates 50 to 100 times higher than their healthy peers. Even in countries with mature vaccination programs, these high-risk children still get hospitalized and still die at disproportionate rates. Roughly 6.8 million U.S. children aged 2 to 18 have conditions that qualify them as high-risk, yet many don't consistently receive all recommended pneumococcal doses.
CAPVAXIVE is designed to fill that gap. It covers 21 bacterial serotypes (the specific strains the vaccine targets), and Merck says those serotypes account for about 78% of invasive pneumococcal disease cases in this high-risk pediatric population. That's a meaningful upgrade over what's currently available for these kids.
The Trial That Made It Happen
The approval rests on a phase 3 study called , which enrolled about 880 children aged 2 to 17 with qualifying chronic conditions. All of them had already completed their standard childhood pneumococcal vaccine series. The trial compared a single dose of CAPVAXIVE against PPSV23, an older polysaccharide vaccine that's been the go-to booster for high-risk kids.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
STRIDE-13
The results were clean. CAPVAXIVE matched PPSV23's immune response for the 12 bacterial strains they share. For the 9 strains unique to CAPVAXIVE, it generated a stronger immune response. That's like matching the incumbent on everything it already does, then covering nine additional bases it can't reach.
Safety looked solid, too. Side effects were mostly injection-site pain, redness, and fatigue, with symptoms lasting a median of about two days. Serious adverse events were comparable between the two groups.
One dose. Broader coverage. Comparable safety. That's the kind of profile that gets guidelines rewritten.
The Real Game: Merck vs. Pfizer in a Multibillion-Dollar Market
To understand why this pediatric nod matters, you need to zoom out.
Pfizer's Prevnar franchise has dominated pneumococcal vaccines for over two decades. Prevnar 13, then Prevnar 20: these products became household names in pediatrician offices worldwide. Pfizer's latest version covers 20 serotypes across both children and adults, making it the Swiss Army knife of pneumococcal prevention.
Merck took a different approach. Instead of building another all-ages product, it designed CAPVAXIVE specifically around the strains causing the most disease in adults. In people 50 and older, CAPVAXIVE's serotypes cover roughly 84% of invasive pneumococcal disease, compared to about 52% for Prevnar 20. That's not a marginal difference; it's a completely different value proposition.
The strategy worked for the adult market. CAPVAXIVE launched in the second half of 2024 and pulled in about $759 million in sales in its first year, with analysts projecting $1.2 billion to $1.6 billion globally by 2026. Not bad for a vaccine that's barely a year old.
But Pfizer had one major card left to play: breadth. Prevnar 20 works in kids and adults. CAPVAXIVE was adults-only. Pediatricians had no reason to think about Merck's vaccine at all.
Until now.
A Trojan Horse Into Pediatrics?
Let's be clear about scope. This isn't a universal pediatric approval. CAPVAXIVE is approved for high-risk kids only, and they need to have already completed their standard childhood pneumococcal series first. It's a complement to existing vaccines, not a replacement.
But strategically, it's a foot in the door. Once a product has a pediatric indication (even a narrow one), it enters a new ecosystem of guidelines, formulary discussions, and physician awareness. Pediatricians and pediatric specialists will now have CAPVAXIVE on their radar. Hospital pharmacies will stock it. The conversations change.
Merck also has Vaxneuvance (PCV15) as its dedicated pediatric pneumococcal vaccine, giving the company a two-pronged franchise: one product anchored in childhood vaccination, another optimized for adults and now extending into high-risk pediatrics. If Merck eventually develops a higher-valent pediatric vaccine aligned with CAPVAXIVE's serotype set, it could offer serotype-matched protection from childhood through old age.
That would be a direct challenge to Pfizer's "one product, all ages" approach.
The Bigger Picture
The pneumococcal vaccine market is worth billions of dollars annually, and the competitive dynamics are shifting faster than they have in years. Pfizer still holds the pole position globally, with deep physician relationships, entrenched contracts, and a pediatric franchise that drives enormous volume. But Merck is chipping away at the edges.
The adult market is where the real revenue battle plays out, and CAPVAXIVE's coverage advantage there is hard to argue with. The pediatric high-risk expansion won't move the revenue needle dramatically on its own. What it does is eliminate one of Pfizer's best talking points: that Prevnar 20 is the only modern pneumococcal conjugate vaccine that works across the age spectrum.
Meanwhile, Vaxcyte is developing a 24-valent pneumococcal vaccine in the background, with encouraging phase 2 data. If that program succeeds post-2026, the three-way competition could reshape the entire market.
For now, though, this is Merck's moment. One year after launching an adult-only vaccine into a market Pfizer had owned for decades, Merck just proved its pneumococcal ambitions don't stop at age 18. The franchise is growing, the serotype story is compelling, and the competitive moat just got a little wider.
Pfizer's move.
5 min read
The Lung Cancer Drug Where Half the Patients Are Still Winning After 7 Years
Seven years into a clinical trial, more than half of metastatic lung cancer patients on Pfizer's lorlatinib still haven't progressed. Oncologists are starting to whisper the word "cure," and the data might actually justify it.
